AstraZeneca Refuels KRAS Push With Jacobio Partnership For Pan-Inhibitor
Deal Snapshot: AstraZeneca will gain global rights to Jacobio’s pan-KRAS inhibitor JAB-23E73 for up to $2bn, after the UK major in November shelved a KRAS G12D inhibitor acquired from Usynova back in 2023.
Scrip - December 22, 2025

RegCell Looks To Bridge Japan-US Expertise As It Builds Treg Cell Capabilities
The firm founded by Treg cell discoverer Shimon Sakaguchi is building up its US team and refining R&D strategy and manufacturing processes to create an example and global path for other Japanese ventures.
Scrip - December 22, 2025

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Regeneron caught between success and expiry; Q3’s top 10 drugs; Lilly’s retatrutide raises weight-loss bar; Pfizer stands by vaccines investment; and Sanofi upbeat despite tolebrutinib tribulations.
Scrip - December 22, 2025

GlucoModicum’s Needle-Free Sofio Could Offer Alternative CGM Approach
The system combines a durable rechargeable transmitter with a two-year life span and a replaceable single-day sensor. The product is intended to address pain, inconvenience and adherence challenges associated with multiweek CGM use.
Medtech Insight - December 22, 2025

Coty Sells Remaining Ownership In Wella, L’Oréal Doubles Galderma Stake; Beauty Deals Roundup
Coty Inc. plans to pay down debt with proceeds from its planned sale of its remaining 25.8% stake in hair care business Wella to KKR & Co. Inc. managed capital accounts. Separately, L’Oréal increases its 10% stake in Galderma to 20%.
HBW Insight - December 20, 2025

Lupin Joines Forces With PolyPeptide For Peptide APIs
Lupin has agreed a “long-term strategic alliance” with CDMO PolyPeptide that the firm says will bolster its supply chain for peptide APIs.
Generics Bulletin - December 19, 2025

UK Bodies Warn Market ‘Not Sustainable’ As Prices Hit ‘Rock Bottom’
The UK generics market risks becoming unsustainable as prices hit “rock bottom,” the House of Lords has been warned in a letter signed by multiple stakeholder associations including Medicines UK.
Generics Bulletin - December 19, 2025

2025 Is A Year Of Firsts As Biosimilars Build Momentum In US
In a busy year for US biosimilars, more than a dozen approvals were seen as multiple brands faced competition for the first time – including Stelara. However, concerns persist over the “biosimilar void”, with hope that the latest FDA announcement on regulatory streamlining can help to fill the gap.
Generics Bulletin - December 19, 2025

Alvotech And Teva Are Latest With US Eylea Settlement
Alvotech and Teva have become the latest Eylea biosimilar developers to announce a settlement allowing a US launch in late 2026. However, first they must clear the hurdle of FDA approval following a recent CRL.
Generics Bulletin - December 19, 2025

Deals Shaping The Industry, November 2025
An interactive look at pharma, medtech and diagnostics deals made during November 2025. Data courtesy of Biomedtracker.
In Vivo - December 18, 2025

Aphaia Pushes A Patient-First Vision For Obesity Care
The obesity field is entering the “sobering” phase of the hype cycle; GLP-1 drugs have opened the door but have limitations. Aphaia CSO Steffen-Sebastian Bolz talks to In Vivo about shifting the focus back to patient experience, not just maximal weight loss.
In Vivo - December 18, 2025

Inductive Bio, Amgen Join ARPA-H’s Push To Replace Animal Tox With AI And Human Tissues
Inductive Bio receives $21m from ARPA-H to develop AI toxicity models using human tissues, partnering with Amgen to replace animal testing in drug development.
In Vivo - December 18, 2025

Health Systems Brace For CAR-T ‘Tsunami’
Industry warns healthcare infrastructure – not manufacturing – may be the real bottleneck as cell therapies eye mass-market diseases.
In Vivo - December 18, 2025